A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
University College, London
University of Pittsburgh
Pfizer
Pfizer
Zealand University Hospital
City of Hope Medical Center
Novartis
Mirati Therapeutics Inc.
GERCOR - Multidisciplinary Oncology Cooperative Group
Compugen Ltd
Intensity Therapeutics, Inc.
NextCure, Inc.
Essen Biotech
Rigshospitalet, Denmark
University of Chicago
Second Affiliated Hospital of Guangzhou Medical University
ADC Therapeutics S.A.
Augusta University
Kineta Inc.
Centre Leon Berard
H. Lee Moffitt Cancer Center and Research Institute